The study of Tau and phospho Tau protein levels in attention deficit and hyperactivity disorder

Background/aim: Attention deficit and hyperactivity disorder (ADHD) is a widespread neurodevelopmental disorder that begins in childhood and has negative consequences throughout adult life. The etiology and pathogenesis of ADHD are still unclear. Tau protein is a soluble microtubule-related protein expressed by neurons and localized in the cytoplasm as well as axons. Tau protein provides stability of microtubule in two ways: phosphorylation and isoforms. The excessive phosphorylation of Tau separates the protein from the microtubule, thus making it unstable. In this study, we aimed to investigate whether there is a relationship between serum Tau protein and phospho Tau (p-Tau181) levels and ADHD occurrence. Materials and methods: This study included 26 male children aged 7–12 years with newly diagnosed ADHD, who had previously not used any medication for ADHD, and 26 male healthy children. Serum Tau and p-Tau181 concentrations were performed by enzymelinked immunosorbent assay (ELISA). Results: In patients, the Tau levels were not significantly different from those of the controls; the p-Tau181 levels were significantly higher than those of the controls. Conclusion: We concluded that high p-Tau181 might be associated with the progression of ADHD and cognitive changes in ADHD.Key words: Attention deficit and hyperactivity disorder, Tau, phospho Tau

PDF

___

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. American Journal of Psychiatry 2007; 164 (6): 942-948. doi: 10.1176/ajp.2007.164.6.942
2. Willcutt EG. The prevalence of DSM-IV attentiondeficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012; 9 (3): 490-499. doi: 10.1007/s13311- 012-0135-8
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 6th ed. Washington, DC, USA; 2000.
4. Bray NJ, O’Donovan MC. The genetics of neuropsychiatric disorders. Brain and Neuroscience Advances 2019; 30; 2. doi: 10.1177/2398212818799271
5. Nizynski B, Dzwolak W, Nieznanski K. Amyloidogenesis of Tau protein. Protein Science 2017; 26 (11): 2126-2150. doi: 10.1002/pro.3275
6. Wang Y, Mandelkow E. Tau in physiology and pathology. Nature Reviews Neuroscience 2016; 17 (1): 5-21. doi: 10.1038/ nrn.2015.1
7. Gao YL, Wang N, Sun FR, Cao XP, Zhang W et al. Tau in neurodegenerative disease. Annals of Translational Medicine 2018; 6(10): 175. doi: 10.21037/atm.2018.04.23
8. Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends in Neuroscience 1998; 21 (10): 428-433. doi: 10.1016/s0166-2236(98)01337-x
9. Demirel ÖF, Cetin I, Turan Ş, Yıldız N, Sağlam T et al. Total Tau and phosphorylated Tau protein serum levels in patients with schizophrenia compared with controls. Psychiatric Quarterly 2017; 88 (4): 921-928. doi: 10.1007/s11126-017-9507-x
10. Lopes S, Vaz-Silva J, Pinto V, Dalla C, Kokras N et al. Tau protein is essential for stress-induced brain pathology. Proceedings of the National Academy of Sciences of the United States of America 2016; 113 (26): E3755-E3763. doi: 10.1073/ pnas.1600953113
11. Dean B, Tsatsanis A, Lam LQ, Scarr E, Duce JA. Changes in cortical protein markers of iron transport with gender, major depressive disorder and suicide. World Journal of Biological Psychiatry 2019; 1-8. doi: 10.1080/15622975.2018.1555377
12. Kadak MT, Cetin I, Tarakçıoğlu MC, Özer ÖF, Kaçar S et al. Low serum level α-synuclein and Tau protein in autism spectrum disorder compared to controls. Neuropediatrics 2015; 46 (6): 410-415. doi: 10.1155/2018/4503871
13. Cetin I, Simsek S. a preliminary study on investigation of serum α-synuclein and Tau protein levels in children with attention deficit hyperactivity disorder. Indian Journal of Clinical Biochemistry 2017; 32 (3): 285-291. doi: 10.1007/ s12291-016-0602-9
14. Süssmuth SD, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neuroscience Letters 2001; 300 (2): 95-98. doi: 10.1016/s0304-3940(01)01556-7
15. Brown EE, Iwata Y, Chung JK, Gerretsen P, Graff-Guerrero A. Tau in late-life depression: a systematic review and metaanalysis. The Journal of Alzheimer’s Disease 2016; 54 (2): 615- 633. doi: 10.3233/JAD-160401
16. Schönknecht P, Hempel A, Hunt A, Seidl U, Volkmann M et al. Cerebrospinal fluid tau protein levels in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 2003; 253 (2): 100-102. doi: 10.1007/s00406-003-0415-8
17. Jaworski J, Psujek M, Bartosik-Psujek H. CSF and serum totaltau and phospho-tau(181P) in MS patients. Central European Journal of Medicine 2011; 6: 193-200. doi: 10.2478/s11536- 011-0003-7
18. Rostasy K, Withut E, Pohl D, Lange P, Ciesielcyk B et al. Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis. Journal of Child Neurology 2005; 20 (10): 822-825. doi: 10.1177/08830738050200100801
19. Schönknecht P, Pantel J, Hunt A, Volkmann M, Buerger K et al. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer’s disease. Neuroscience Letters 2003; 339 (2): 172-174. doi: 10.1016/ s0304-3940(02)01481-7